Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$521M |
| 2 |
Nike
NKE
|
+$509M |
| 3 |
Micron Technology
MU
|
+$439M |
| 4 |
Super Micro Computer
SMCI
|
+$435M |
| 5 |
Broadcom
AVGO
|
+$329M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$5.31B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.89B |
| 3 |
Amazon
AMZN
|
+$1.48B |
| 4 |
Microsoft
MSFT
|
+$1.07B |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$904M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 2.38% |
| 2 | Consumer Discretionary | 1.03% |
| 3 | Financials | 0.75% |
| 4 | Healthcare | 0.67% |
| 5 | Communication Services | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11276
CALL
Zevra Therapeutics
ZVRA
$697M
| $59.3K | ﹤0.01% |
12,100
-27,200
| -69% | -$129K |
|
11277
Nuvation Bio
NUVB
$2.44B
| $59.3K | ﹤0.01% |
+20,299
| New | +$61.9K |
|
|
LNAI
11278
CALL
Lunai Bioworks
LNAI
$10.9M
| $59K | ﹤0.01% |
421
+221
| +111% | +$30.1K |
|
|
TOUR
11279
Tuniu
TOUR
$52.4M
| $58.9K | ﹤0.01% |
+7,043
| New | +$65.6K |
|
|
MRNS
11280
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $58.9K | ﹤0.01% |
50,300
-103,300
| -67% | -$258K |
|
11281
PUT
Shattuck Labs
STTK
$793M
| $58.7K | ﹤0.01% |
15,200
-130,700
| -90% | -$1.06M |
|
11282
Cocrystal Pharma
COCP
$21.6M
| $58.4K | ﹤0.01% |
25,052
-27,078
| -52% | -$52.8K |
|
|
ORIO
11283
PUT
Orion Digital Corp
ORIO
$19.5M
| $58.4K | ﹤0.01% |
39,700
+7,500
| +23% | +$12.9K |
|
11284
CALL
CEMIG Preferred Shares
CIG
$5.66B
| $58.3K | ﹤0.01% |
33,150
-61,100
| -65% | -$117K |
|
|
EGRX
11285
CALL
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $58.2K | ﹤0.01% |
+10,400
| New | +$45.3K |
|
11286
GSI Technology
GSIT
$224M
| $58.2K | ﹤0.01% |
21,961
-20,674
| -48% | -$67.4K |
|
11287
PUT
Verastem
VSTM
$669M
| $57.8K | ﹤0.01% |
19,400
+8,700
| +81% | +$71.7K |
|
|
CNSL
11288
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $57.8K | ﹤0.01% |
13,131
+1,553
| +13% | +$6.72K |
|
|
AUTL
11289
PUT
Autolus Therapeutics
AUTL
$620M
| $57.8K | ﹤0.01% |
16,600
-43,400
| -72% | -$187K |
|
|
ASTR
11290
CALL
DELISTED
Astra Space, Inc. Class A Common Stock
ASTR
| $57.7K | ﹤0.01% |
115,400
-13,700
| -11% | -$8.36K |
|
11291
Eledon Pharmaceuticals
ELDN
$272M
| $57.5K | ﹤0.01% |
21,788
-77,990
| -78% | -$186K |
|
|
CVAC
11292
PUT
DELISTED
CureVac
CVAC
| $57.5K | ﹤0.01% |
16,900
-12,800
| -43% | -$41.9K |
|
11293
Dragonfly Energy
DFLI
$16.9M
| $57.3K | ﹤0.01% |
752
-224
| -23% | -$17.4K |
|
11294
Orion Energy Systems
OESX
$102M
| $57.2K | ﹤0.01% |
5,156
-1,505
| -23% | -$14.7K |
|
11295
CALL
PetMed Express
PETS
$38.8M
| $57.1K | ﹤0.01% |
14,100
-24,000
| -63% | -$102K |
|
11296
Humacyte
HUMA
$189M
| $56.8K | ﹤0.01% |
11,841
-111,791
| -90% | -$582K |
|
|
PIM
11297
Franklin Master Intermediate Income Trust
PIM
$152M
| $56.8K | ﹤0.01% |
+17,613
| New | +$55.7K |
|
11298
RF Industries
RFIL
$115M
| $56.5K | ﹤0.01% |
16,202
+5,765
| +55% | +$17.9K |
|
|
CNSL
11299
CALL
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $56.3K | ﹤0.01% |
12,800
| – | – |
|
11300
Gilat Satellite Networks
GILT
$783M
| $56.2K | ﹤0.01% |
12,563
-14,045
| -53% | -$74.7K |
|
Similar funds
Jeff Yass's Q2 2024 Portfolio in Review
As of Q2 2024, Jeff Yass held 13,638 positions worth $537B, down 6.7% from $576B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass's Q2 2024 filing shows 1,591 new, 4,593 increased, 5,607 reduced and 1,726 closed positions. Its largest new stake was NextEra Energy 7.299% Corporate Units: 2,575,000 shares worth $127M. The largest sale was NVIDIA, an estimated $5.31B.
By sector, the portfolio is most concentrated in Technology at 2.4% of assets, down from 3% a quarter earlier, followed by Consumer Discretionary and Financials.
- Jeff Yass's largest Q2 2024 buy was NextEra Energy 7.299% Corporate Units: 2,575,000 shares worth $127M.
- Jeff Yass added most to Vanguard FTSE Developed Markets ETF in Q2 2024, an estimated $521M increase.
- Jeff Yass's biggest Q2 2024 reduction was NVIDIA, cutting an estimated $5.31B.
- Jeff Yass fully exited iShares MSCI USA Quality Factor ETF in Q2 2024, selling an estimated $26.2M.
- Jeff Yass's ten largest holdings make up 26% of its $537B portfolio in Q2 2024.
- Jeff Yass opened 1,591 new positions and closed 1,726 in Q2 2024.
- Jeff Yass's portfolio value fell 6.7% quarter-over-quarter to $537B.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.